Amgen said this week that its $415 million proposed acquisition of Icelandic genetics research firm Decode will bolster its ability to evaluate which molecules to advance through its pipeline.
Meanwhile, Amgen has no interest in keeping up Decode's direct-to-consumer genomics business. As such, Amgen's purchase of Decode will essentially whittle down an already small DTC genetic testing market to a single player: 23andMe.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
